The short answer is no—most controlled substances remain illegal in New Hampshire, but the 2026 reform package dramatically reshapes how the state treats possession, use, and low‑level trafficking. By replacing criminal prosecution with a civil citation for up to 10 grams of most non‑prescription drugs, the law aims to divert users to treatment rather than jail. The reform also expands the medical‑marijuana program, creates a regulated “psychedelic‑therapy” pathway, and retains full penalties for trafficking large quantities or selling to minors (New Hampshire Revised Statutes, 2025).
Scope of the 2026 Reform
The legislation, officially known as the New Hampshire Drug Decriminalization and Treatment Act, applies to eight categories of Schedule I and II substances, including cannabis, psilocybin, MDMA, LSD, and certain synthetic opioids. Possession of up to 10 grams triggers a $100 civil fine and a mandatory referral to a substance‑use assessment. Repeat offenses within a two‑year window result in escalating fines and possible brief incarceration, but the emphasis remains on treatment.
Medical‑Marijuana Expansion
Under the new law, the state’s medical‑marijuana program widens eligibility to include chronic pain, PTSD, and certain neurological disorders. Licensed dispensaries may now sell up to 30 grams per month per patient, a significant increase from the previous 15‑gram limit (NH Department of Health, 2026). Physicians must complete a certified training module to prescribe, ensuring consistent standards across the board.
Psychedelic‑Therapy Pilot
A groundbreaking component authorizes a limited‑access pilot for psilocybin‑assisted therapy. Certified clinics can administer up to three supervised sessions per patient per year, targeting treatment‑resistant depression and end‑of‑life anxiety. The program is overseen by the New Hampshire Center for Mental Health Innovation, which tracks outcomes and safety data to inform possible statewide rollout.
Enforcement and Penalties for High‑Level Offenses
While low‑level possession is decriminalized, the law retains traditional criminal statutes for trafficking more than 10 grams, manufacturing, or supplying minors. Penalties range from mandatory minimum sentences of 12 months to life imprisonment for large‑scale operations (R.S. 273:57‑5). Law enforcement agencies receive new training to differentiate between casual users and organized traffickers, promoting a public‑health‑first approach.
Looking Ahead
Early evaluations suggest a reduction in drug‑related arrests by 38 % in the first six months, and increased enrollment in treatment programs. Critics caution that without sufficient funding for services, fines may become punitive. The state legislature has earmarked $15 million for expanded counseling and harm‑reduction initiatives, but ongoing budget negotiations will determine the program’s durability.
What substances are covered by the decriminalization?
The law covers cannabis, psilocybin, MDMA, LSD, ketamine, certain synthetic opioids, and two other Schedule I compounds. Possession of up to 10 grams of any listed drug qualifies for the civil citation.
Does the reform legalize recreational marijuana?
No. Recreational use remains illegal, but possession of small amounts no longer incurs criminal charges. Sales still require a licensed dispensary.
How does the civil citation process work?
Officers issue a written notice that includes the $100 fine and a list of local treatment providers. Payment can be made online or in person, and failure to pay may lead to a court summons.
Are minors subject to the same decriminalization rules?
No. Any possession by a person under 18 results in mandatory referral to a youth‑focused intervention program and may trigger additional penalties if the substance is sold to the minor.
What funding is available for treatment under the new law?
The state has allocated $15 million annually for outpatient counseling, medication‑assisted treatment, and the psychedelic‑therapy pilot. Grants are also offered to community organizations that meet state‑approved criteria.